Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Long-Term Debt Repayments (2018 - 2024)

Cytosorbents posted quarterly Long-Term Debt Repayments of $4.4 million for Q2 2024, up 600.0% on a QoQ basis from $625000.0 in Q1 2024.

Cytosorbents (CTSO) has 3 years of Long-Term Debt Repayments data on file, last reported at $4.4 million in Q2 2024.

  • For the quarter ending Q2 2024, Long-Term Debt Repayments changed N/A year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2024 stood at $5.0 million (changed N/A YoY), and the FY2024 full-year result was $5.0 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q2 2024 stood at $4.4 million, up from $625000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q4 2020 and bottomed at $625000.0 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Cytosorbents 28.81 Mn 24.01 Mn 6.13 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 4.38 Mn
Jun 30, 2024 4.38 Mn
Mar 31, 2024 625,000.00
Mar 31, 2024 625,000.00
Dec 31, 2020 15.00 Mn
Dec 31, 2020 15.00 Mn
Mar 31, 2018 666,667.00
Mar 31, 2018 666,667.00